Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

TG Therapeutics, Inc. - Common Stock (NQ:TGTX)

41.33 +1.03 (+2.56%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TG Therapeutics, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Why TG Therapeutics Shares Are Trading Lower Today
TG Therapeutics Inc (NASDAQ: TGTX) is trading lower Monday after the company announced worse-than-expected second-quarter financial results and H.C. Wainwright lowered its... 
Via Benzinga
TG Therapeutics Stock Plunged As H.C. Wainwright Cuts Target Price After Disappointing Q2
H.C. Wainwright has lowered TG Therapeutics Inc's (NASDAQ: 
Via Benzinga
Mid-Afternoon Market Update: Nasdaq Gains 50 Points; Marin Software Shares Plummet
Toward the end of trading Monday, the Dow traded up 0.02% to 34,941.69 while the NASDAQ rose 0.37% to 14,727.42. The S&P also rose, gaining 0.10% to 4,399.45. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
Here's Why TG Therapeutics Stock Is Getting Hammered Today
A second-quarter earnings report reminded investors how difficult it is for independent companies to launch new cancer drugs. 
Via The Motley Fool
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock increased by 35.01% to $5.5 during Monday's regular session. Trading volume for Xenetic Biosciences's stock is 10.1... 
Via Benzinga
Earnings Scheduled For May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report... 
Via Benzinga
Mid-Day Market Update: Crude Oil Down 2.5%; Exicure Shares Spike Higher
Midway through trading Monday, the Dow traded up 0.35% to 35,058.26 while the NASDAQ rose 0.52% to 14,748.83. The S&P also rose, gaining 0.39% to 4,412.29. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
40 Stocks Moving In Monday's Mid-Day Session
Gainers Ever-Glory International Group, Inc. (NASDAQ: EVK) shares jumped 133% to $5.27 after the company announced a $5 million stock repurchase program. Exicure, Inc. (NASDAQ:... 
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Global Payments Posts Upbeat Q2 Earnings
Following the market opening Monday, the Dow traded up 0.58% to 35,138.90 while the NASDAQ rose 0.40% to 14,731.03. The S&P also rose, gaining 0.46% to 4,415.36. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Earnings Scheduled For August 2, 2021
Companies Reporting Before The Bell • HSBC Holdings (NYSE:HSBC) is estimated to report earnings for its second quarter. • Addex Therapeutics (NASDAQ:ADXN) is... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Brickell Biotech (NASDAQ:BBI) stoc... 
Via Benzinga
Looking Into TG Therapeutics's Return On Capital Employed
During Q1, TG Therapeutics's (NASDAQ:TGTX) reported sales totaled $793.00 thousand. Despite a 2.07% in earnings, the company posted a loss of $88.73 million. In Q4, TG... 
Via Benzinga
Return On Capital Employed Overview: TG Therapeutics
In Q1, TG Therapeutics (NASDAQ:TGTX) posted sales of $793.00 thousand. Earnings were up 2.07%, but TG Therapeutics still reported an overall loss of $88.73 million. In Q4, TG... 
Via Benzinga
TG Therapeutics' Ublituximab-Umbralisib Combo Application Under FDA Review for Hematological Malignancies
The FDA has accepted for review TG Therapeutics Inc's (NASDAQ: TGTX) marketing application seeking approval for ublituximab in combination with Ukoniq (... 
Via Benzinga
Exposures Product Safety
TG Therapeutics Inc (TGTX) Q1 2021 Earnings Call Transcript
TGTX earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Recap: TG Therapeutics Q1 Earnings
Shares of TG Therapeutics (NASDAQ:TGTX) remained unaffected after the company reported Q1 results. Quarterly Results Earnings per share were down 43.75% year over year to... 
Via Benzinga
The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes
After having declined through the first half of the week, biotech stocks staged a recovery to close higher in the trading week ended May 28. Broader market sentiment and company-... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2021
Upgrades Compass Point upgraded the previous rating for Newtek Business Services Corp (NASDAQ:NEWT) from Neutral to Buy. For the fourth quarter, Newtek Business Services... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.